Sidmap / Hirshberg Foundation

About SIDMAP
SiDMAP, a leader in the field of metabolomics, provides metabolic profiling and phenotyping services to pharmaceutical, biotech and research organizations involved in drug discovery and development and in the analysis of disease states. SiDMAP has a proprietary method for tracking the presence or absence of heavy carbons to learn about energy flow and metabolite synthesis patterns in various biochemical pathways. Using a nonradioactive isotope – for instance a neutron-enriched carbon in glucose or fatty acids – SiDMAP routinely analyzes up to 240 different pathways and biochemical reactions simultaneously. The technology has been used successfully (in partnership with various pharmaceutical companies and academic institutions) in mechanism-of-action and toxicity studies of therapeutics for various indications including cancer, the metabolic syndrome and various neurodegenerative diseases. In addition to cellular and animal studies, the SiDMAP technology is being used in humans to develop biomarkers for identifying patients best suited for particular therapeutics.

About The Hirshberg Foundation
The ultimate goal of Hirshberg Foundation for Pancreatic Cancer Research is to identify an early diagnostic tool to improve treatment options and extend life of newly diagnosed patients. The foundation has been supporting pancreatic cancer research in the United States since 1998. Now in their tenth year, the Foundation’s dedicated efforts have significantly raised awareness and understanding about pancreatic cancer, a disease that continues to be one of the most fatal and least funded of all cancer types.